Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
2. Surufatinib
1. 1308672-74-3
2. Surufatinib
3. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
4. Hmpl-012
5. Kdr-in-1
6. 1816307-67-1
7. Hmpl012
8. Surufatinib [inn]
9. Surufatinib [usan]
10. B2k5l1l8s9
11. N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
12. Benzenemethanesulfonamide, N-(2-(dimethylamino)ethyl)-3-((4-((2-methyl-1h-indol-5-yl)oxy)-2-pyrimidinyl)amino)-
13. Benzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1h-indol-5-yl)oxy]-2-pyrimidinyl]amino]-
14. Sulanda
15. N-[2-(dimethylamino)ethyl]-1-[3-({4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl}amino)phenyl]methanesulfonamide
16. Sulfatinib [who-dd]
17. Sulfatinib; Hmpl-012
18. Unii-b2k5l1l8s9
19. Surufatinib [who-dd]
20. Gtpl9769
21. Schembl1822601
22. Chembl4297190
23. Bcp14757
24. Ex-a2524
25. Nsc797937
26. Who 10349
27. Akos030632837
28. Zinc117218067
29. Cs-5949
30. Db15106
31. Nsc-797937
32. Ac-35852
33. As-74954
34. Hmpl-012;hmpl 012;hmpl012
35. Hy-12297
36. Vegfr2 Inhibitor [wo2011060746]
37. D71057
38. A926546
39. N-(2-(dimethylamino) Ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
40. N-(2-(dimethylamino) Ethyl)-1-(3-((4-(2-methyl-1h-indol-5-yloxy) Pyrimidin-2-yl) Amino) Phenyl) Methanesulfonamide
| Molecular Weight | 480.6 g/mol |
|---|---|
| Molecular Formula | C24H28N6O3S |
| XLogP3 | 3.4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 10 |
| Exact Mass | 480.19435995 g/mol |
| Monoisotopic Mass | 480.19435995 g/mol |
| Topological Polar Surface Area | 121 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 733 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of haematopoietic and lymphoid tissue
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Surufatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Surufatinib, including repackagers and relabelers. The FDA regulates Surufatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Surufatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Surufatinib supplier is an individual or a company that provides Surufatinib active pharmaceutical ingredient (API) or Surufatinib finished formulations upon request. The Surufatinib suppliers may include Surufatinib API manufacturers, exporters, distributors and traders.
Surufatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Surufatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Surufatinib GMP manufacturer or Surufatinib GMP API supplier for your needs.
A Surufatinib CoA (Certificate of Analysis) is a formal document that attests to Surufatinib's compliance with Surufatinib specifications and serves as a tool for batch-level quality control.
Surufatinib CoA mostly includes findings from lab analyses of a specific batch. For each Surufatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Surufatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Surufatinib EP), Surufatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Surufatinib USP).
LOOKING FOR A SUPPLIER?
